Short answer
Moderna (MRNA) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.3B (up 29.2% year over year) with net income of $162M.
Q3 2026 key financials · XBRL
- Revenue
- $1.3B
- +29.2% YoY · +805.5% QoQ
- Net income
- $162M
- +181.0% YoY · +120.7% QoQ
- Operating margin
- 9.9%
- EPS (diluted)
- $0.43
- +184.3% YoY · +121.9% QoQ
Source: XBRL data from the Moderna (MRNA) Q3 2026 10-Q on SEC EDGAR. USD.
Moderna Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added convertible-notes risk, triggered by issuance of 0.00% Convertible Senior Notes due 2032
- Liquidity risk: insufficient cash or financing for maturity repayment, conversion settlements, or fundamental-change repurchases
- Default risk: credit agreement restrictions could prevent cash payments required under the notes’ indenture
- Dilution risk: share-based conversion may dilute stockholders and pressure common-stock prices
- Counterparty risk: uncapped exposure to financial institutions under unsecured capped call transactions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Moderna quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.